<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760574</url>
  </required_header>
  <id_info>
    <org_study_id>202010105RIND</org_study_id>
    <nct_id>NCT04760574</nct_id>
  </id_info>
  <brief_title>Association Between Human Immunodeficiency Virus (HIV) Infection and Male Hypogonadism</brief_title>
  <official_title>Association Between Human Immunodeficiency Virus (HIV) Infection and Male Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cross-sectional study investigating the prevalence of hypogonadism in HIV-infected MSM&#xD;
      population&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we conduct a cross-sectional study investigating the prevalence of&#xD;
      hypogonadism in HIV-infected MSM population. Age-matched non-HIV infected MSM group will be&#xD;
      used as comparison group. We will also determine the risk factors associated with male&#xD;
      hypogonadism (age, duration of HIV infection, comorbidities, BMI, ART use). Correlation will&#xD;
      be made between serum testosterone levels and sexual function, vitality, exercise capacity,&#xD;
      mood, and bone mineral density.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2021</start_date>
  <completion_date type="Anticipated">November 2030</completion_date>
  <primary_completion_date type="Anticipated">November 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Symptoms of androgen deficiency</measure>
    <time_frame>2021-2030</time_frame>
    <description>We use the score of Androgen Deficiency in Aging Males (ADAM) questionnaire to study the prevalence of hypogonadism in HIV-infected MSM population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum free testosterone</measure>
    <time_frame>2021-2030</time_frame>
    <description>We use serum free testosterone to study the prevalence of hypogonadism in HIV-infected MSM population</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Hypogonadism; Ovarian</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <description>HIV infected men who have sex with men</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>HIV non-infected men</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Serum total testosterone and free testosterone level</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cross-sectional study investigating the prevalence of hypogonadism in HIV-infected MSM&#xD;
        population. Age-matched non-HIV infected group will be used as comparison group&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-infected men who have sex with men&#xD;
&#xD;
          -  HIV non-infected men&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of testosterone supplement, anabolic steroid in the past one year.&#xD;
&#xD;
          -  History of pituitary , adrenal or gonad diseases&#xD;
&#xD;
          -  History of pituitary surgery or radiation therapy&#xD;
&#xD;
          -  History of systemic chemotherapy&#xD;
&#xD;
          -  Active opportunistic infection under treatment&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Severe hepatic, renal or cardiac impairment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shyang-Rong Shih, Ph.D.</last_name>
    <phone>+886-2-2312-3456</phone>
    <phone_ext>61613</phone_ext>
    <email>srshih@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shyang-Rong Shih, Ph.D.</last_name>
      <phone>+886-2-2312-3456</phone>
      <phone_ext>61613</phone_ext>
      <email>srshih@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

